Many studies across a variety of disciplines have identified differences in health status, health care access, and health care utilization by race/ethnicity. [1] [2] [3] [4] [5] During the past few years, however, there has been an effort by public health organizations and government agencies to call increased national attention to the importance of addressing issues of racial/ethnic disparities in health in a systematic fashion. There is increased national attention explicitly focused on the goal of eliminating, not simply reducing, health disparities between segments of the population, including members of racial and ethnic groups. 6 At the same time, there has also been a virtual revolution in the treatment options available to HIV-infected people in the United States. Given the substantial evidence that use of HIV-related medications strongly predicts health outcomes among both individuals and populations, it is important to understand what determines medication access. A good deal of research has focused on determining whether access to or utilization of HIVrelated medications differs by race/ethnicity.
In an effort to gain a broader understanding of racial/ethnic differences in utilization of antiretroviral medications and prophylactic medications, we performed a systematic literature review. In this article, we first present a brief history of the introduction of antiretroviral medications and the evolution of HIV treatment guidelines. We then describe the results of our literature search and review of studies examining the possible link between race/ethnicity status and utilization of HIV medications.
Background
In 1987, zidovudine (AZT) became the first antiretroviral drug to be approved by the Food and Drug Administration (FDA) for the treatment of HIV disease, specifically for the treatment of advanced disease. Additional nucleoside analogs to receive FDA approval were didanosine in 1991, zalcitabine in 1992, stavudine in 1994, lamivudine in 1995, and abacavir in 1998. The first protease inhibitor to be approved was saquinavir, in 1995, with subsequent approvals for ritonavir and indinavir in 1996, nelfinavir in 1997, amprenavir in 1999, and a lopinavir/ritonavir combination in 2000. In the mid-1990s, non-nucleoside reverse transcriptase inhibitors (NNRTIs) received FDA approval, starting with nevirapine in 1996, followed by delavirdine in 1997, and efavirenz in 1998 (see FDA website for detailed information on approval dates). 7 Early published HIV treatment guidelines 8 recommended initiating therapy with zidovudine in symptomatic individuals with CD4 cell counts Ͻ500 cells/ mm 3 and asymptomatic individuals with CD4 counts Ͻ200 cells/mm 3 . No antiretroviral therapy was recommended for asymptomatic individuals with CD4 cell counts in the 200-500 cells/mm 3 range, and no antiretroviral therapy was suggested for asymptomatic individuals with CD4 cell counts Ͼ500 cells/mm 3 . Monotherapy with zidovudine or another nucleoside analog remained the recommended standard until 1996, when the International AIDS Society-USA Panel recommended combination nucleoside therapy, with the addition of protease inhibitors reserved for individuals at higher risk of progression. 9 These were the first consensus panel guidelines to include HIV RNA (viral load) level as a criterion for initiation and modification of antiretroviral therapy. The Panel on Clinical Practices for the Treatment of HIV, convened in 1996 by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation, published its antiretroviral guidelines for adults and adolescents in 1998. 10 These guidelines are updated regularly, with the most recent information available electronically on the HIV/AIDS Treatment Information Service website. 11 In the late 1990s, clinical trials demonstrated the high efficacy of triple combination therapies containing a protease inhibitor or an NNRTI, now widely referred to as highly active antiretroviral therapy (HAART). [12] [13] [14] [15] Surveillance data showed declines in both AIDS incidence and mortality in the United States from 1996 to 1998, 16 a trend that coincided with increased availability of HAART. Furthermore, several observational studies provided important data on the effectiveness of antiretrovirals, measured as a decrease in AIDS incidence and mortality. [17] [18] [19] [20] In 2000, revised guidelines from the Department of Health and Human Services recommended treatment for all symptomatic individuals (regardless of CD4 cell count or viral load) and an option to treat asymptomatic individuals with Ͻ500 CD4 cells/mm 3 or a viral load Ͼ10,000 copies/ml. 21 Due to accumulating evidence about treatment side effects, guidelines published more recently have adopted a more conservative approach, with explicit recognition that "clinical benefit has been demonstrated in controlled trials only for patients with CD4+ T cells Ͻ200/mm 3 ." 22 These guidelines recommend initiating treatment only to symptomatic patients and to asymptomatic individuals with CD4 counts Ͻ200 cells/mm 3 . The guidelines state that "treatment should generally be offered, though controversy exists," for asymptomatic individuals with CD4 cell counts in the 200-350 cells/mm 3 range (regardless of viral load), and the guidelines urge a frank discussion of the lack of consensus among experts with respect to treatment for asymptomatic individu-als with CD4 counts Ͼ350 cells/mm 3 and viral loads Ͻ30,000 copies/ml. 23 Recommended treatment regimens include two specified nucleoside analogs plus either a protease inhibitor, a protease inhibitor combination, or an NNRTI. 23 The 2000 guidelines (and updates thereafter) were, however, released after completion of data collection for all the studies included in this review.
The earliest HIV-related treatment guidelines did not address antiretroviral therapy but rather prophylaxis against Pneumocystis carinii pneumonia (PCP). 24, 25 Guidelines for prophylaxis against PCP and other opportunistic infections have been updated regularly. [26] [27] [28] [29] [30] The 1995 U.S. Public Health Service/Infectious Disease Society of America guidelines for the prevention of opportunistic infections recommended trimethoprim-sulfamethoxazole as the preferred agent for primary prophylaxis of PCP, and dapsone plus pyrimethamine plus leucovorin as a second-line regimen. 31 At this point, other regimens including clindamycin plus primaquine, atovaquone, aerosolized pentamidine, and intravenous trimetrexate were to be considered only in "unusual situations in which the recommended agents cannot be administered." 31 Rifabutin was recommended for primary prophylaxis of Mycobacterium avium complex (MAC). 31 In 1997, aerosolized pentamidine was recommended as a second-line agent for PCP prophylaxis. 29 The strength of the recommendation for MAC prophylaxis was upgraded, and the first-line agent recommendation was switched to clarithromycin or azithromycin. 29 In 1999, dapsone without pyrimethamine and atovaquone was added to the list of potential second-line agents for PCP prophylaxis. 30 The most significant change in these guidelines, however was the discussion about preliminary evidence that suggested providers might wish to discontinue PCP prophylaxis in patients who had achieved sustained (3-6 months) CD4 count elevations Ͼ200 in response to HAART. 32 
METHODS
We performed a detailed Web-based search of scientific publications for articles entered in the MEDLINE/ HealthSTAR database of the University of California from January 1, 1985, through October 1, 2001. We set parameters of "English language" and "human subjects" and used the following standard subject (MeSH) headings, either alone or in selected combination: acquired immunodeficiency syndrome, HIV, HIV infections, anti-HIV agents, health services, health services accessibility, health services needs and demands, and health services research. We then expanded the search process by identifying potential additional articles from references cited in articles obtained through our initial search.
We selected references for inclusion in this review on the basis of their ability to meet all of the following criteria: (a) published in peer-reviewed scientific journals; (b) presented and analyzed original data from U.S. populations; (c) included quantitative measures of outpatient use of antiretroviral medications (i.e., among non-institutionalized patients) and/or outpatient use of medications for prophylaxis against opportunistic infections as outcome variables; and (d) analyzed race/ethnicity as a potential predictor of outpatient antiretroviral or prophylactic medication use, and explicitly presented results of those analyses. We excluded references that reported only adherence to medications because the study populations were limited to patients who received prescriptions.
We found 28 references that met the above criteria. These references were published from 1991 to 2001, and presented data that were collected from 1984 to 1999.
RESULTS

Antiretroviral use
The reported overall range of use of antiretroviral agents ranged from 43% to 95% (with most rates clustering in the 50% to 75% range) across studies examined in this analysis. These studies included different populations, different medications (e.g., all antiretrovirals vs. classes of antiretrovirals vs. single agents), different study periods, and different time frames for medication use (e.g., ever used vs. using currently vs. used within a specified recent period of time). As would be expected, substantial changes have been observed in the reported rates of use of specific classes of agents and specific single agents over time, as newer agents have become available and treatment guidelines have changed.
In a study of 305 people with AIDS in Boston in 1990-1991, 95% of participants reported ever receiving zidovudine. 33 This high rate of reported use is reflective of the sample selected; all participants had an advanced disease stage (i.e., an AIDS diagnosis), and all were recruited from clinical care settings. 33 In the AIDS Cost and Service Utilization Survey (ACSUS) conducted in 1991, which included a larger sample with a broader spectrum of disease, use of zidovudine in the prior three months ranged from 59% among asymptomatic individuals to 67% among individuals with AIDS. 35 In an early analysis of 1,415 men at all sites of the Multicenter AIDS Cohort Study (MACS) in 1990-1992, recent use of zidovudine was reported by 68% to 77% of the cohorts. 38 In contrast, analysis of data for 1991-1996 found that among 307 men at the Baltimore MACS site, only 43% reported at their most recent study visit having used antiretroviral medications in the prior six months. 43 Another study in Baltimore found among 838 people who presented to the Johns Hopkins AIDS Service in 1990-1992 that 58% of African Americans and 63% of whites reported current antiretroviral use. 39 Somewhat later, in 1993-1995, 70% of 863 HIVpositive women enrolled in the HIV Epidemiology Research Study (HERS) reported ever having used antiretrovirals, but only 43% reported current use. 41 HERS findings offered new insights because, unlike participants in the studies described above, HERS participants were not recruited exclusively from medical care settings. In 1996, a study of 224 people receiving HIV medical care in St. Louis found that 98% of clients reported having heard of AZT and 83% of these reported having taken the drug. 45 Among 1,034 adults recruited from a Los Angeles-area AIDS service organization, 66% reported taking a protease inhibitor in November 1996. 46 Among injection drug users with AIDS who were enrolled in New Jersey Medicaid in 1988-1996, 74% had a prescription filled for at least one antiretroviral medication. 42 This database was later examined for use of newer antiretrovirals; among 2,089 adults with AIDS who received New Jersey Medicaid benefits in 1996-1998, 65% had received at least one prescription for a protease inhibitor or NNRTI. 55 The HIV Cost and Services Utilization Study (HCSUS) surveys a nationally representative probability sample of HIV-infected adults receiving regular medical care in the contiguous United States. In the HCSUS cohort, the cumulative proportion of patients who reported having ever received HAART increased from 37% in late 1996 to 71% in early 1998. Nevertheless, only 53% were "currently" using HAART at the time of this second follow-up interview. 54 In comparison, by 1998 fully 87% of the MACS participants reported having ever used antiretroviral therapy, 81% reported "current" use of any antiretrovirals, and only 63% reported "current" use of potent antiretroviral therapy (HAART). 52 Among 764 Johns Hopkins AIDS Service patients (interviewed in 1998-1999) with a CD4 nadir Ͻ500 cells/mm 3 and peak HIV RNA Ͼ30,000 copies/ml, 93% reported having ever used antiretrovirals, 76% reported having ever used HAART, and 48% reported current use of HAART. 56 Three additional studies provide information about unique subpopulations of HIV-infected people. Among 2,607 HIV-infected women who were receiving New York Medicaid benefits and who had delivered a baby in 1993-1996, the proportion of women prescribed antiretrovirals during the second or third trimester of pregnancy increased from 12% in 1993 to 51% in 1996. 44 In a study examining the effect of housing status on health care utilization among New York Medicaid recipients in 1996-1997, 68% of homeless people reported current use of any antiretrovirals, compared with 78% of people in stable housing situations. 51 Among 327 HIV-infected adolescents ages 12-18 years enrolled in the Reaching for Excellence in Adolescent Care and Health (REACH) study in 1996-1999, 25% had been prescribed HAART by the time of study enrollment. 57 Among those not on HAART by enrollment, 53% were prescribed HAART during their first two years in the study. 57
Associations between race/ethnicity and use of antiretroviral medications
Overall, 26 studies evaluated the effect of race and/or ethnicity on the use of antiretroviral medications. (See Table 1 .) Overall, 15 studies had data collection periods that included 1996 or later, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] i.e., after FDA approval for use of the first protease inhibitor in late 1995. Ten of the these reports specifically measured the use of either protease inhibitors, NNRTIs, or HAART. [45] [46] [47] [48] 50, [53] [54] [55] [56] [57] Overall, 14 studies found a negative association between non-white race and antiretroviral use in one or more multivariate analyses. 32, [36] [37] [38] [39] [45] [46] [47] [48] [52] [53] [54] [55] Among these 14, eight studies found only a negative association across all outcomes assessed, 32, [36] [37] [38] [39] 45, 55, 56 and six studies found mixed results depending on the specific outcome measure. 37, 45, 48, [52] [53] [54] Three studies found a positive association with at least one antiretroviral use measure, 40, 44, 48 two of which found either no association 44 or a negative association 48 across a different measure of antiretroviral use. Sixteen studies found no association between race/ethnicity and at least one measure of antiretroviral use; [33] [34] [35] 37, [41] [42] [43] [44] [45] [49] [50] [51] [52] [53] [54] 57 however, five of these also found a negative association on at least one antiretroviral use measure, 37, 45, [52] [53] [54] and one also found a positive association. 44 In four of these studies an association between race/ethnicity and antiretroviral use explicitly noted in bivariate analyses lost statistical significance after adjustment for other covariates. 49, 50, 53, 54 Negative association with use of antiretrovirals (n = 14 studies). In all 14 of these studies, people whose race/ ethnicity was other than white had a lower likelihood than white study participants of receipt of antiretrovirals after adjustment for potential confounders (such as insurance status, income, and disease stage) in multivariate models. The earliest study was a cross-sectional survey of 880 adults with AIDS or symptomatic HIV recruited from community-based organizations and public hospital clinics across nine cities in the United States. 29 In a logistic regression model that adjusted for level of illness, injection drug use, gender, and insurance status, whites were more likely to report being offered AZT than non-whites (odds ratio [OR] = 1.73; 95% confidence interval [CI] 1.11, 2.69). 32 McLaughlin et al. performed an analysis of data on 366 patients (age Ͼ12 years) with an index AIDS diagnosis in 1989-1991 (limited to AIDS patients who had continuous enrollment in New Jersey Medicaid before the AIDS diagnosis and who had not received any antiretrovirals or PCP prophylaxis during the year prior to an AIDS diagnosis). 37 After adjustment for age, injection drug use, gender, primary source of care, and year of AIDS diagnosis, non-whites were less likely to have had any Medicaid claim for AZT following the AIDS diagnosis than whites (OR = 0.76; 95% CI 0.5, 0.9). 37 Crystal et al. found that among 478 adults with AIDS or symptomatic HIV enrolled in the New Jersey Medicaid waiver program in 1987-1988, African Americans were almost half as likely (OR = 0.46; 95% CI 0.31, 0.69) to have ever used zidovudine (measured via claims data) as whites in analyses controlled for age, gender, injection drug use, and health status. 37 This racial disparity in zidovudine use was not statistically significant, however, among 828 Medicaid recipients who enrolled slightly later, in 1989-1990 (OR = 0.79; 95% CI 0.57, 1.08). 37 This suggests the possibility that racial disparities were eliminated quickly as zidovudine became a more widely accepted treatment. Results from other studies, however, suggest that nonwhites remain less likely than whites to use zidovudine and other antiretrovirals. For example, data from 586 HIV-positive adults with a CD4 count Յ500 cells/mm 3 from Johns Hopkins for 1990-1992 showed that African Americans were less likely than whites to be on antiretrovirals at presentation to the clinic (OR = 0.59; 95% CI 0.38, 0.93) after data were adjusted for age, gender, income, insurance, education, injection drug use, residence in East Baltimore, and duration of HIV infection. 39 During a similar time period, among 1,415 HIV-positive men without AIDS in the MACS cohort, whites were more likely to use antiretrovirals than nonwhites (OR = 1.58; 95% CI 1.12, 2.07) after data were adjusted for age, income, education, CD4 cell count, symptoms, insurance status, hospitalization, and outpatient service use. 38 Mixed findings were noted in subsequent analyses of data on 673 men seen for a MACS study visit in 1998. 52 Racial disparities appeared to persist among men with a CD4 count Ͼ500 cells/ mm 3 , with African American men being more likely to have never used antiretrovirals than white or Hispanic men (OR = 3.2; 95% CI given graphically from Ͼ1 to about 12), 52 after adjustment for CD4 cell count, and number of outpatient visits. No association between race and "never use" was found when analyses were limited to men with a CD4 cell count of Ͻ500 cells/ mm 3 . 52 Among 152 HIV-infected patients with a CD4 count Ͻ500 cells/mm 3 receiving care at a St. Louis clinic, African American patients were more likely to report having never taken AZT than white patients (OR = 3.139; 95% CI 1.084, 9.094), after adjustment for CD4 count. 45 Racial/ethnic disparities in use of newer antiretroviral medication regimens (e.g., protease inhibitors and NNRTIs) have also been documented. [45] [46] [47] [48] [53] [54] [55] [56] For example, Jeffe et al. found that African Americans were more likely to never have heard of protease inhibitors (OR = 7.62; 95% CI 3.02, 19.21) or NNRTIs (OR = 4.91; 95% CI 1.74, 13.85). 45 In a 1996 study conducted in the Los Angeles area among 881 HIVpositive clients of a large HIV/AIDS community services organization, non-English speakers had a greater likelihood of not taking a protease inhibitor (OR = 2.46; 95% CI 1.30, 4.64) than English speakers. 46 Data on 2,776 HIV-positive adults enrolled in the HCSUS showed that African Americans were significantly less likely to have received any HAART by December 1996 (OR = 0.44, pՅ0.001), even after adjustment for predisposing variables, need variables, and enabling variables. 47 Another HCSUS publication reported antiretroviral use by December 1996 in a slightly different manner, specifically as lack of receipt of any protease inhibitor or NNRTI 53 rather than receipt of HAART. 47 Blacks (OR = 2.16; 95% CI 1.54, 3.05) and Latinos (OR = 1.48; 95% CI 1.10, 1.99) were more likely than whites to have not received protease inhibitors or NNRTIs after adjustment for age, gender, CD4 cell count, HIV exposure category, insurance status, education, and geographic region. 53 In a subsequent analysis covering HCSUS data for 1996-1998, black race was independently associated with lower use of HAART (OR = 0.68; 95% CI 0.43, 0.95) in models that included CD4 count and gender by exposure (e.g., female injection drug user); however, race lost statistical significance in a model that also included insurance status, education, and geographic region (OR = 0.74; 95% CI 0.51, 1.07). 54 The study with the largest sample size (using claims data for 24,646 HIV-positive adults enrolled in Florida Medicaid in 1993-1997) found divergent results depending on the outcome evaluated. After adjustment for age, gender, income, health status measures, and other demographics in a marginal effects probit model, blacks had a 0.04 higher probability of receiving a regimen comprised of two nucleosides than whites (pՅ0.01). 48 With respect to newer regimens containing a protease inhibitor plus two nucleosides, the reverse association was observed; blacks had a 0.01 (pՅ0.01) lower probability of receiving this regimen. 48 Among 2,089 adults included in an analysis of linked New Jersey HIV/AIDS registry and New Jersey Medicaid data, the difference in use of protease inhibitors or NNRTIs narrowed from a 23.7 percentage point difference between African Americans and whites in 1996 to a 7.2 percentage point difference in 1998. 55 The difference between Hispanics and whites narrowed from 17.1 percentage points in 1996 to 10.1 in 1998. 55 In a multivariate model inclusive of all years (1996, 1997, 1998) , both African Americans (OR = 0.58; 95% CI 0.45, 0.75) and Hispanics (OR = 0.65; 95% CI 0.47, 0.88) were less likely to have received a protease inhibitor or NNRTI than whites, after adjustment for age at diagnosis, gender, exposure category, year of diagnosis, insurance status, vital status, and county of residence. 55 In a study of 764 HIV-infected patients interviewed at the Johns Hopkins AIDS Service from late 1998 through late 1999, blacks were found to have a higher likelihood than whites of never having used HAART (OR = 1.8; 95% CI 1.1, 3.1) after adjustment for gender, CD4 cell count nadir, peak HIV RNA, prior opportunistic infection, and heroin/cocaine use. 56 Positive association with use of antiretrovirals (n = 3 studies). In an analysis of ACSUS data for 1991-1992, African Americans (OR = 1.30; 95% CI 1.04, 1.62) and Hispanics (OR = 1.38; 95% CI 1.11, 1.72) were more likely to be using antiretrovirals than whites, after adjustment for age, gender, injection drug use, insurance status, income, health service use measures, health status measures, and social support measures. 40 In an analysis of New York Medicaid claims from 1,282 women who delivered a baby in 1994-1996, and after publication of clinical trial results suggesting zidovudine reduces the risk of vertical transmission, Latinas were more likely (OR = 2.59; 95% CI 1.76, 3.80) to have been prescribed zidovudine during their second or third trimester of pregnancy. 41 As mentioned above, Anderson et al. found blacks had a 0.04 higher probability of receiving a regimen comprised of 2 nucleosides than whites. 45 No association with use of antiretrovirals (n = 16). Overall, 16 studies did not find an association between race/ ethnicity and at least one measure of antiretroviral use. [33] [34] [35] 37, [41] [42] [43] [44] [45] [49] [50] [51] [52] [53] [54] 57 Among them, seven found a statistically significant association between race/ethnicity and one of the study's measures of antiretroviral use, 37, 44, 45, [52] [53] [54] and therefore were discussed in above sections.
Ten studies failed to find a significant association across any antiretroviral use outcome assessed by the authors. [33] [34] [35] [41] [42] [43] [44] [49] [50] [51] 57 Among these ten, five reported on sample sizes of Ͻ350. 30, 31, 40, 47, 54 were HAART-naive at study enrollment. 57 The remaining five studies were not substantially different from the studies which found a negative association in terms of sample size, population selection, or overall methodology. 35, 41, 42, 49, 51 Specifically, Hellinger et al. evaluated recent AZT use among 1,949 HIV-infected adults and adolescents in the ACSUS study; 35 Solomon et al. evaluated any antiretroviral use among 863 HIV-infected women enrolled in the HERS; 41 Sambamoorthi et al. assessed prescription claims data (e.g. at least one antiretroviral prescription) among 2,600 injection drug users with AIDS captured in a merged New Jersey Medicaid-AIDS registry database; 42 
Associations between race and/or ethnicity and use of medications for PCP prophylaxis
Overall, 11 studies evaluated potential associations between race/ethnicity and use of medications for PCP prophylaxis (Table 2) . 33, 36, [38] [39] [40] [41] 45, 51, 53, 58, 59 Four studies found that subjects whose race/ethnicity was not white were less likely to use PCP prophylaxis, 36, 39, 41, 53 of which one study found a negative association between non-white race/ethnicity and one measure of PCP prophylaxis but no association for another measure. 41 None of the studies found non-whites more likely to use PCP prophylaxis. Eight studies did not find any association, 33 The cohort for PCP prophylaxis was different than the cohort for prophylaxis for other opportunistic infections ( Negative association with PCP prophylaxis (n = 4 studies).
Among 366 patients enrolled in New York Medicaid in 1989-1991, claims data revealed non-whites were less likely to have received PCP prophylaxis (OR = 0.57; 95% CI 0.4, 0.7) compared with whites, after adjustment for age, gender, injection drug use, year of AIDS diagnosis, and primary source of care. 35 Among 283 HIV-infected patients with CD4 counts Յ200 cells/ mm 3 presenting to the Johns Hopkins AIDS Service in 1990-1992, blacks were less likely to have used PCP prophylaxis at study entry compared with whites (OR = 0.27; 95% CI 0.13, 0.56) after adjustment for age, gender, injection drug use, insurance status, income, education, residence in East Baltimore, and duration of HIV infection. 39 Solomon et al. found that African Americans were less likely to have ever received PCP prophylaxis (OR = 0.34; 95% CI 0.13, 0.85) but just as likely to be currently receiving it (OR approximately 0.5, 95% CI approximately 0.2, 0.9, given graphically) among 863 HIV-infected women enrolled in HERS. 41 In this study, Hispanic women were also less likely to have ever received PCP prophylaxis than whites (OR approximately 0.3; 95% CI approximately 0.1, 0.9, given graphically). 41 Among approximately 1,500 HIVinfected patients with a CD4 count Ͻ200 cells/mm 3 in the HCSUS, blacks were more likely to report not having received PCP prophylaxis in the past six months (OR = 1.54; 95% CI 1.03, 2.29). 53 No association with PCP prophylaxis (n = 8 studies). Among these eight studies, only two have not been described in prior sections of this review. 58 Negative association with prophylaxis for other opportunistic infections (n = 3). Three studies also evaluated use of medications for prophylaxis of opportunistic infections other than PCP (Table 3) . 41, 58, 59 Two found non-whites were less likely to be using indicated medications, 41, 58 and one found no association. 59 Specifically, Solomon et al. found that African American women were less likely to report use of prophylaxis for non-PCP oppor-tunistic infections than white women (OR = 0.50; 95% CI 0.30, 0.83), after adjustment for injection drug use, study site, and CD4 count. 41 Similarly, Sackoff et al. found that prescription for MAC prophylaxis was less likely in blacks compared with whites (OR = 0.08; 95% CI 0.01, 0.52), after controlling for number of outpatient visits, clinic site, and eligible intervals for study observation. 58 Murphy at al. did not find an association between race/ethnicity and MAC prophylaxis. 59 
DISCUSSION
African Americans and Latinos remain disproportionately affected by the HIV epidemic. 60 People of color have also historically had limited access to a variety of health care services, 61, 62 including HIV-related medical services. For example, previous studies among people with HIV infection have found that non-whites are less likely to have outpatient visits and more likely to have emergency room visits than whites. 43, 63, 64 Among people with AIDS, non-whites are also more likely to have no insurance or public insurance. 65 The studies we identified in our literature review cover a 16-year period of data collection (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , during which HIV-related treatment guidelines were in rapid evolution. Furthermore, these studies used a variety of data sources (survey, claims data, chart review), measured race/ethnicity in a variety of ways (multiple categories vs. white/non-white), measured the outcomes in a variety of ways (both time period of medication use and coding of medications), and analyzed the data by a variety of methods (cross-sectional, longitudinal). These differences make it difficult to readily draw a simple conclusion from comparing the studies; nevertheless, careful evaluation of this body of literature as a whole does provide a different kind of insight than can be gleaned from any individual study.
A preliminary listing of articles measuring antiretroviral use reveals that 14 articles found a negative association between non-white race/ethnicity and antiretroviral use in at least one multivariate model, 31,34-37,45-48,52-56 three articles found a positive association in at least one multivariate model, 40, 44, 48 and 10 articles found no association in either bivariate or multivariate analyses for all the antiretroviral use outcomes assessed by the authors. [33] [34] [35] [41] [42] [43] [49] [50] [51] 57 A more detailed look at these studies yields patterns that help place these results in perspective. For example, among the 10 articles that failed to find any association across all outcomes examined, seven relied on cross-sectional survey data, [33] [34] [35] 41, 43, 50, 51 and four had sample sizes less than 350. 33 The cohort for OI prophylaxis was different from the cohort for PCP prophylaxis ( investigators to detect an effect, had such an effect truly existed. The possibility of this limitation is further supported by the fact that seven [33] [34] [35] 41, 43, 50, 51 out of the 12 studies that performed cross-sectional analyses [31] [32] [33] [34] [35] 39, 41, 43, 45, 46, 50, 51, 57 and five 33, 34, 43, 50, 57 out of seven studies with analytic sample sizes less than 350 33, 34, 43, 45, 52, 57 found no association. In contrast, only three 42, 49, 57 out of 14 studies that performed longitudinal analyses, [36] [37] [38] 40, 42, 44, [47] [48] [49] [52] [53] [54] [55] 57 and five 35, 41, 42, 49, 51 out of 20 studies with analytic sample sizes greater than 350 32, [35] [36] [37] [38] [39] [40] [41] [42] 43, [46] [47] [48] [49] [51] [52] [53] [54] [55] [56] [57] failed to find any association between race/ethnicity and antiretroviral use. Among those studies that did identify an association between race/ethnicity and antiretroviral use, the overwhelming majority, 13 of 16, found a negative association, 32, [36] [37] [38] [39] [45] [46] [47] [52] [53] [54] [55] [56] two found a positive association, 40, 44 and one found both negative and positive associations. 48 Given the general trend in ethnic/racial disparities across a variety of illnesses, the finding of greater use of antiretrovirals among people of nonwhite race/ethnicity is an unexpected one. In one of the studies, African Americans were more likely to be excluded from the analyses than were whites because of missing data; therefore, the authors concede that it is difficult to interpret this unexpected result. 37 One study differed systematically from all the other studies in that it focused only on zidovudine treatment during pregnancy. 44 As the main intent of this therapy was to reduce mother-to-child transmission rather than to treat the maternal infection, it is not inconceivable that the positive association between Latino ethnicity and receipt of zidovudine may reflect provider assumptions about the relative risk of mother-to-child HIV transmission and/or racial/ethnic differences in perceptions about potential risks and benefits of AZT to prevent transmission. In the study that found both a negative and a positive association, blacks were more likely to receive two nucleosides, and less likely to receive a protease inhibitor plus two nucleosides. 48 These findings suggest that the elevated probability of receiving two nucleosides may represent decreased access to newer, state-of-the art regimens.
Based on all of these considerations, our summary interpretation of this literature is that there is a preponderance of evidence across time and across subpopulations that HIV-infected people of color in the United States have experienced a lower rate of utilization of antiretroviral medications than HIV-infected white people.
Interestingly, while there is some evidence to suggest non-whites are also at risk for a lower rate of use of prophylaxis against opportunistic infections, the strength of the evidence is not as strong as it was for antiretroviral use. Only four 36, 39, 41, 53 out of 11 studies 34, 36, [38] [39] [40] [41] 45, 51, 53, 58, 59 found a negative association between non-white race/ethnicity and use of PCP prophylaxis. One might speculate that there was greater penetration of PCP prophylaxis because PCP prophylaxis was available and recommended before antiretroviral use, and because PCP prophylaxis regimens have been much more stable over time than recommended antiretroviral regimens. While this may in part be true, the recent HCSUS finding that blacks are less likely to have received PCP prophylaxis in the past six months indicate that the picture may be more complex. 53 With the advent of new and more efficacious antiretroviral therapies, access to and utilization of antiretrovirals has emerged as an important determinant of health outcomes. Thus, the substantial scientific evidence that racial and/or ethnic minorities are at risk for a lower rate of use of HIV-related medications, even after adjustment for important covariates such as health status and health insurance status, has particularly troubling implications for the future health outcomes of at-risk populations. Our challenge now is to shift the focus from documenting differences to aggressively developing, implementing, and evaluating strategies to eliminate these disparities.
